PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC

被引：0
|
作者：
Vokes, Natalie I. [1 ,2 ]
Le, Xiuning [1 ]
Yap, Timothy A. [1 ,3 ,4 ,5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Therapeut Discovery Div, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Khalifa Inst Personalized Canc Therapy, Houston, TX USA
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 18期
关键词：
CELL LUNG-CANCER; PTEN EXPRESSION; IMPACT;
D O I：
10.1158/1078-0432.CCR-24-1188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these mutations decreased osimertinib sensitivity in EGFR-mutated non-small cell lung cancer. The AKT inhibitor capivasertib was found to overcome this resistance, providing an important rationale for the development of AKT inhibitors in non-small cell lung cancer.
引用
收藏
页码：3968 / 3970
页数：3
相关论文
共 50 条
  • [21] Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match
    Leighl, Natasha B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (07): : 652 - 654
  • [22] Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
    Brouns, Anita J. W. M.
    van Veelen, Ard
    Veerman, G. D. Marijn
    Steendam, Christi
    Dursun, Safiye
    van der Leest, Cor
    Croes, Sander
    Dingemans, Anne-Marie C.
    Hendriks, Lizza E. L.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05):
  • [23] Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies
    Leonetti, A.
    Verze, M.
    Minari, R.
    Perrone, F.
    Gnetti, L.
    Bordi, P.
    Pluchino, M.
    Nizzoli, R.
    Azzoni, C.
    Bottarelli, L.
    Lagrasta, C. A. M.
    Mazzaschi, G.
    Buti, S.
    Gasparro, D.
    Cosenza, A.
    Ferri, L.
    Majori, M.
    De Filippo, M.
    Ampollini, L.
    La Monica, S.
    Alfieri, R.
    Silini, E. M.
    Tiseo, M.
    BRITISH JOURNAL OF CANCER, 2024, 130 (01) : 135 - 142
  • [24] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Mei-Mei Zheng
    Yang-Si Li
    Hai-Yan Tu
    Hao Sun
    Kai Yin
    Ben-Yuan Jiang
    Jin-Ji Yang
    Xu-Chao Zhang
    Qing Zhou
    Chong-Rui Xu
    Zhen Wang
    Hua-Jun Chen
    De-Xiang Zhou
    Yi-Long Wu
    BMC Medicine, 20
  • [25] Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies
    A. Leonetti
    M. Verzè
    R. Minari
    F. Perrone
    L. Gnetti
    P. Bordi
    M. Pluchino
    R. Nizzoli
    C. Azzoni
    L. Bottarelli
    C. A. M. Lagrasta
    G. Mazzaschi
    S. Buti
    D. Gasparro
    A. Cosenza
    L. Ferri
    M. Majori
    M. De Filippo
    L. Ampollini
    S. La Monica
    R. Alfieri
    E. M. Silini
    M. Tiseo
    British Journal of Cancer, 2024, 130 : 135 - 142
  • [26] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Sun, Hao
    Yin, Kai
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    Xu, Chong-Rui
    Wang, Zhen
    Chen, Hua-Jun
    Zhou, De-Xiang
    Wu, Yi-Long
    BMC MEDICINE, 2022, 20 (01)
  • [27] Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
    Hackner, Klaus
    Buder, Anna
    Hochmair, Maximilian J.
    Strieder, Matthaeus
    Grech, Christina
    Fabikan, Hannah
    Burghuber, Otto C.
    Errhalt, Peter
    Filipits, Martin
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2021, 15
  • [28] Osimertinib in EGFR-Mutated Lung Cancer REPLY
    Herbst, Roy S.
    Wu, Yi-Long
    Tsuboi, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 676
  • [29] Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
    Crowley, Fionnuala
    Fitzgerald, Bailey G.
    Bhardwaj, Aarti S.
    Siraj, Irine
    Smith, Cardinale
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
  • [30] Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis
    Yi, Lilan
    Fan, Junsheng
    Qian, Ruolan
    Luo, Peng
    Zhang, Jian
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (01) : 284 - 294
12345